Aladdin®Ligands of Immunopharmacology
Aladdin®Ligands of Immunopharmacology

Product Manager:Harrison Michael
Introduction
At the forefront of life sciences and biomedical research, immunopharmacological ligands, as key tools, are leading new breakthroughs and discoveries. Immune ligands are small molecules, antibodies, and cytokines that can precisely bind to important receptors, cytokines, and signaling pathways in the immune system. They promote the advancement of immunopharmacology by regulating immune responses, studying mechanisms of inflammation, and exploring autoimmune diseases.
The application of immunopharmacological ligands spans all stages from basic research to clinical applications. Researchers use these ligands to deeply analyze the activation process of immune cells, reveal the signaling pathways of cytokines, and explore immune regulatory mechanisms. This not only helps us better understand the human immune system but also provides valuable clues for the development of innovative immune therapies.
Aladdin Scientific, in the field of immunopharmacological ligands, provides strong support for scientists with its rich product variety and high-quality R&D level. Our immune ligand products cover targets of various immune receptors, cytokines, and signaling pathways, allowing researchers to choose the right tools to meet their research needs. Whether exploring the basic mechanisms of the immune system or developing new therapeutic methods, our products aim to be a reliable partner on your scientific journey.
Activator
Cat.No | Product Name | CAS | Research Category | Size |
N,N-Dimethylimidodicarbonimidic diamide (AMPK activator) | 657-24-9 | Metabolism | 250mg;1g;5g;25g | |
ML 265 (PKM1/2 activator) | 1221186-53-3 | Metabolism | 5mg;10mg;25mg;50mg;100mg | |
Gabapentin (Kv7.3 activator) | 60142-96-3 | Ion channel | 5g;25g;100g;500g | |
SRT2104 (GSK2245840) (SIRT1 activator) | 1093403-33-8 | Cell cycle | 5mg;25mg;100mg | |
Omaveloxolone (RTA-408) | 1474034-05-3 | REDOX | 2mg;5mg;10mg;25mg; 50mg;100mg |
Agonist
Cat.No | Product Name | CAS | Research Category | Size |
6-OAU (GPR84 full agonist) | 83797-69-7 | G protein-coupled receptors | 5mg;25mg;100mg | |
BMS202 (PD-1/PD-L1 inhibitor 2) | 1675203-84-5 | G protein-coupled receptors | 1mg;5mg;10mg; 25mg;50mg;100mg | |
BRL-15572 | 193611-72-2 | G protein-coupled receptors | 1mg;5mg;10mg;50mg | |
L-Adrenaline | 51-43-4 | G protein-coupled receptors | 1g;5g;25g | |
Ponesimod (S1P1 receptor agonist) | 854107-55-4 | G protein-coupled receptors | 5mg;10mg;25mg;50mg;100mg | |
SCH 336 (CB1 receptor inverse agonist) | 447459-51-0 | G protein-coupled receptors | 10mg;25mg;50mg | |
Ozanimod (RPC1063) | 1306760-87-1 | G protein-coupled receptors | 5mg;10mg;25mg;50mg;100mg | |
Olodaterol (ADRB2 agonist) | 868049-49-4 | G protein-coupled receptors | 5mg;10mg;25mg;100mg | |
Vortioxetine | 508233-74-7 | G protein-coupled receptors | 10mg;50mg;250mg;1g | |
Salmeterol (ADRB2 full agonist) | 89365-50-4 | G protein-coupled receptors | 5mg;10mg;25mg;50mg; | |
Brimonidine (ADRA2A full agonist) | 59803-98-4 | G protein-coupled receptors | 250mg;1g;5g | |
Indacaterol (ADRB1 agonist) | 312753-06-3 | G protein-coupled receptors | 10mg;50mg;250mg | |
TIC10 (ONC201) (IGF-1R agonist) | 1616632-77-9 | Protein tyrosine kinase | 5mg;10mg;50mg; 100mg;200mg | |
2',3'-cGAMP Sodium Salt | 1441190-66-4 | Immunity and inflammation | 1mg;5mg;10mg | |
Motolimod (VTX-2337) (TLR8 agonist) | 926927-61-9 | Immunity and inflammation | 1mg;5mg;25mg | |
Tapinarof | 79338-84-4 | Immunity and inflammation | 25mg;100mg;250mg;1g | |
6α-Methyl-11β-hydroxyprogesterone (Glucocorticoid receptor agonist) | 2668-66-8 | Endocrinology and hormones | 25mg;100mg;250mg | |
Beclomethasone dipropionate | 1327543 | Endocrinology and hormones | 250mg;1g;5g;25g | |
Desoximetasone | 382-67-2 | Endocrinology and hormones | 50mg;100mg;250mg;1g | |
Deflazacort (GR agonist) | 14484-47-0 | Endocrinology and hormones | 1g;5g | |
Desonide (GR agonist) | 638-94-8 | Endocrinology and hormones | 250mg;1g;5g;25g | |
Budesonide | 51333-22-3 | Endocrinology and hormones | 50mg;100mg;250mg;1g;5g | |
Prednisone (GR agonist) | 19420 | Endocrinology and hormones | 1g;5g;25g | |
Triamcinolone acetonide | 76-25-5 | Endocrinology and hormones | 250mg;1g;5g;25g | |
Fluorometholone | 426-13-1 | Endocrinology and hormones | 250mg;1g;5g | |
Fluocinonide | 356-12-7 | Endocrinology and hormones | 25mg;100mg;250mg;500mg | |
Hydrocortisone | 50-23-7 | Endocrinology and hormones | 1g;5g;25g;100g | |
Ciclesonide | 126544-47-6 | Endocrinology and hormones | 5mg;25mg;100mg;500mg | |
fluticasone furoate (GR agonist) | 397864-44-7 | Endocrinology and hormones | 25mg;50mg;100mg; 250mg;1g;5g | |
Mometasone | 105102-22-5 | Endocrinology and hormones | 5mg;25mg;50mg;100mg | |
Fluocinolone Acetonide | 67-73-2 | Endocrinology and hormones | 250mg;1g;5g;25g | |
SX-682 (TRAIL agonist) | 1648843-04-2 | Apoptosis | 5mg;10mg;25mg;50mg;100mg | |
Fingolimod (KCa3.4 agonist) | 162359-55-9 | Ion channel | 50mg;250mg;1g;5g |
Allosteric Modulator
Cat.No | Product Name | CAS | Research Category | Size |
AZ 3451 (PAR2 inhibitor) | 2100284-59-9 | G protein-coupled receptors | 5mg;10mg;25mg;50mg;100mg | |
Reparixin (CXCR2 inhibitor) | 266359-83-5 | G protein-coupled receptors | 1mg;5mg;25mg;100mg | |
BMS-345541 (IKK inhibitor) | 547757-23-3 | NF-κB signaling pathway | 5mg;10mg;25mg;50mg;100mg |
Antagonist
Cat.No | Product Name | CAS | Research Category | Size |
AH 6809 (DP1 receptor antagonist) | 33458-93-4 | G protein-coupled receptors | 10mg;50mg;100mg | |
AMG 853 (DP1 receptor antagonist) | 1169483-24-2 | G protein-coupled receptors | 5mg;10mg;25mg;50mg;100mg | |
AZD 2098 (CCR4 antagonist) | 566203-88-1 | G protein-coupled receptors | 5mg;10mg;25mg;50mg;100mg | |
AZD1981 (DP2 receptor antagonist) | 802904-66-1 | G protein-coupled receptors | 5mg;25mg | |
AZD5069 (CXCR1 antagonist) | 878385-84-3 | G protein-coupled receptors | 5mg;10mg;25mg; | |
Avacopan (CCX168) (C5a1 receptor antagonist) | 1346623-17-3 | G protein-coupled receptors | 5mg;10mg;25mg;50mg | |
BX 471 (CCR1 antagonist) | 217645-70-0 | G protein-coupled receptors | 5mg;10mg;25mg;50mg;100mg | |
Ciforadenant (CPI-444) | 1202402-40-1 | G protein-coupled receptors | 5mg;25mg;100mg | |
GLPG 0974 (FFA2 receptor antagonist) | 1391076-61-1 | G protein-coupled receptors | 1mg;5mg;10mg;25mg | |
GSK 2239633A (CCR4 antagonist) | 1240516-71-5 | G protein-coupled receptors | 1mg;5mg;10mg;25mg;50mg; | |
GW 627368 (EP4 receptor antagonist) | 439288-66-1 | G protein-coupled receptors | 1mg;5mg;10mg;25mg;50mg;250mg | |
LY255283 (BLT1 receptor antagonist) | 117690-79-6 | G protein-coupled receptors | 1mg;5mg;10mg;25mg;50mg;100mg | |
NE 52-QQ57 (GPR4 antagonist) | 1401728-56-0 | G protein-coupled receptors | 2mg;5mg;10mg;25mg;50mg;100mg | |
Navarixin (SCH-527123) | 473727-83-2 | G protein-coupled receptors | 5mg;25mg;100mg | |
ONO-AE3-208 (EP3 receptor antagonist) | 402473-54-5 | G protein-coupled receptors | 5mg;10mg;25mg;50mg | |
PF 04418948 (EP2 receptor antagonist) | 1078166-57-0 | G protein-coupled receptors | 5mg;10mg;25mg;50mg;100mg | |
RE 201 (AT1 receptor antagonist) | 254740-64-2 | G protein-coupled receptors | 25mg;50mg;100mg;250mg | |
RS 102895 (CCR2 antagonist) | 300815-41-2 | G protein-coupled receptors | 1mg;5mg;10mg;25mg;50mg;100mg | |
RS504393 (CCR2 antagonist) | 300816-15-3 | G protein-coupled receptors | 5mg;25mg | |
SB 225002 (CXCR2 antagonist) | 182498-32-4 | G protein-coupled receptors | 5mg;10mg;50mg;100mg | |
SB 328437 (CCR3 antagonist) | 247580-43-4 | G protein-coupled receptors | 5mg;10mg;25mg;50mg;100mg | |
Setipiprant (ACT-129968) | 866460-33-5 | G protein-coupled receptors | 25mg;100mg | |
Montelukast (CysLT1 receptor antagonist) | 158966-92-8 | G protein-coupled receptors | 100mg;250mg;1g;5g | |
Preladenant | 377727-87-2 | G protein-coupled receptors | 5mg;10mg;25mg;50mg;100mg | |
Verlukast (CysLT1 receptor antagonist) | 120443-16-5 | G protein-coupled receptors | 5mg;25mg | |
Melatonin (5-HT2B receptor antagonist) | 73-31-4 | G protein-coupled receptors | 5g;25g;100g;500g | |
cenicriviroc (CCR5 antagonist) | 497223-25-3 | G protein-coupled receptors | 1mg;5mg;25mg;100mg | |
danirixin (CXCR2 antagonist) | 954126-98-8 | G protein-coupled receptors | 1mg;5mg;10mg;25mg;50mg; | |
Fexofenadine (H1 receptor antagonist) | 83799-24-0 | G protein-coupled receptors | 250mg;1g;5g;25g | |
Maraviroc (CCR5 antagonist) | 376348-65-1 | G protein-coupled receptors | 5mg;25mg;100mg | |
S1RA (SIGMAR1 antagonist) | 878141-96-9 | Ion channel | 5mg;10mg;25mg; | |
Gefapixant (P2X3 antagonist) | 1015787-98-0 | Ion channel | 5mg;10mg;25mg;50mg;100mg | |
H 151 (STING antagonist) | 941987-60-6 | Immunity and inflammation | 5mg;10mg;50mg;100mg;250mg | |
TAK-242 (TLR4 antagonist) | 243984-11-4 | Immunity and inflammation | 1mg;5mg;10mg;50mg;100mg | |
YM 90709 (IL5R antagonist) | 163769-88-8 | Immunity and inflammation | 2mg;10mg;50mg;250mg | |
ABT-199 (GDC-0199) | 1257044-40-8 | Apoptosis | 5mg;10mg;25mg; | |
Lifitegrast (integrin, alpha L subunit (CD11A) antagonist) | 1025967-78-5 | Cytoskeleton | 25mg;100mg;250mg;1g |
Channel Blocker
Cat.No | Product Name | CAS | Research Category | Size |
YM-58483 (BTP2) | 223499-30-7 | Ion channel | 1mg;5mg;10mg; 25mg;50mg;100mg | |
NS 6180 (KCa3.1 inhibitor) | 353262-04-1 | Ion channel | 10mg;50mg;250mg | |
Forsythoside B (TRPV3 inhibitor) | 81525-13-5 | Ion channel | 5mg;25mg;50mg;100mg | |
Diclofenac (ASIC3 relevant agents) | 15307-86-5 | Ion channel | 1g;5g;25g;100g;500g | |
Acetylsalicylic acid | 50-78-2 | Ion channel | 250g;1kg | |
Iberiotoxin (KCa1.1 relevant agents) | 129203-60-7 | Ion channel | 1mg | |
2-(3-Trifluoromethylanilino)benzoic Acid | 530-78-9 | Ion channel | 5g;25g;100g | |
Salicylic acid (ASIC3 relevant agents) | 69-72-7 | Ion channel | 100g;250g;500g; 1kg;2.5kg;5kg |
Inhibitor
Cat.No | Product Name | CAS | Research Category | Size |
TH 5487 (OGG1 inhibitor) | 2304947-71-3 | DNA damage and repair | 25mg;50mg;100mg | |
PJ34 (PARP1 inhibitor) | 344458-19-1 | DNA damage and repair | 5mg;10mg;25mg; | |
Celastrol (RGS17 inhibitor) | 34157-83-0 | G protein-coupled receptors | 10mg;50mg | |
(R)-Lisofylline (STAT4 inhibitor) | 100324-81-0 | JAK/STAT signaling pathway | 2mg;5mg;10mg;25mg;50mg | |
Abrocitinib (PF-04965842) | 1622902-68-4 | JAK/STAT signaling pathway | 5mg;10mg;25mg;50mg;100mg | |
Decernotinib (VX-509) (JAK1 inhibitor) | 944842-54-0 | JAK/STAT signaling pathway | 2mg;5mg;10mg;25mg;50mg;100mg | |
PF-06700841 (JAK1 inhibitor) | 1883299-62-4 | JAK/STAT signaling pathway | 5mg;10mg;25mg;50mg;100mg | |
Upadacitinib (JAK1 inhibitor) | 1310726-60-3 | JAK/STAT signaling pathway | 50mg;100mg;250mg;500mg | |
Itacitinib (INCB39110) (JAK1 inhibitor) | 1334298-90-6 | JAK/STAT signaling pathway | 5mg;10mg;25mg; | |
Ritlecitinib (PF-06651600) (JAK1 inhibitor) | 1792180-81-4 | JAK/STAT signaling pathway | 5mg;10mg;25mg;50mg;100mg | |
Tofacitinib (JAK1 inhibitor) | 477600-75-2 | JAK/STAT signaling pathway | 5mg;25mg;100mg;500mg;1g | |
Solcitinib (JAK1 inhibitor) | 1206163-45-2 | JAK/STAT signaling pathway | 5mg;25mg | |
S-Ruxolitinib (INCB018424) | 941685-37-6 | JAK/STAT signaling pathway | 1mg;5mg;10mg;25mg;50mg;100mg | |
BMS-582949 (MAPK14 inhibitor) | 623152-17-0 | MAPK signaling pathway | 1mg;5mg;25mg;50mg;100mg | |
CC-930 (MAPK10 inhibitor) | 899805-25-5 | MAPK signaling pathway | 5mg;10mg;25mg;50mg;100mg | |
Losmapimod (MAPK14 inhibitor) | 585543-15-3 | MAPK signaling pathway | 5mg;10mg;25mg; | |
MW-150 (MAPK14 inhibitor) | 1628502-91-9 | MAPK signaling pathway | 1mg;5mg;10mg;25mg;50mg;100mg | |
PH-797804 (MAP3K11 inhibitor) | 586379-66-0 | MAPK signaling pathway | 5mg;10mg;25mg;100mg | |
SB 202190 (MAPK14 inhibitor) | 152121-30-7 | MAPK signaling pathway | 5mg;25mg;100mg | |
Selonsertib (GS-4997) (MAP3K5 inhibitor) | 1448428-04-3 | MAPK signaling pathway | 5mg;25mg;100mg;500mg | |
TAK-715 (MAPK11 inhibitor) | 303162-79-0 | MAPK signaling pathway | 1mg;5mg;25mg;100mg | |
TCS JNK 5a (MAPK10 inhibitor) | 312917-14-9 | MAPK signaling pathway | 5mg;10mg;25mg; | |
VX-745 (MAPK 11 inhibitor) | 209410-46-8 | MAPK signaling pathway | 10mg;25mg;50mg;100mg;250mg | |
Pamapimod (MAPK10 inhibitor) | 449811-01-2 | MAPK signaling pathway | 1mg;5mg;10mg; | |
Vemurafenib (PLX4032, RG7204) | 918504-65-1 | MAPK signaling pathway | 10mg;25mg;50mg; | |
SP600125 (MAPK10 inhibitor) | 129-56-6 | MAPK signaling pathway | 25mg;50mg;100mg; 500mg;1g;5g | |
Bentamapimod | 848344-36-5 | MAPK signaling pathway | 5mg;10mg;50mg;100mg | |
Doramapimod (MAPK11 inhibitor) | 285983-48-4 | MAPK signaling pathway | 10mg;50mg;250mg | |
GSK8612 (IKBKE inhibitor) | 2361659-62-1 | NF-κB signaling pathway | 2mg;5mg;10mg;25mg;50mg;100mg | |
MLN120B (IKBKB inhibitor) | 783348-36-7 | NF-κB signaling pathway | 5mg;10mg;25mg;50mg;100mg | |
MRT67307 (IKBKE inhibitor) | 1190378-57-4 | NF-κB signaling pathway | 5mg;10mg;25mg;50mg;100mg | |
Amlexanox (IKBKE inhibitor) | 68302-57-8 | NF-κB signaling pathway | 250mg;1g;5g | |
AMG319 (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha inhibitor) | 1608125-21-8 | PI3K/Akt/mTOR | 5mg;10mg;25mg;50mg;100mg | |
AS-252424 (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha inhibitor) | 900515-16-4 | PI3K/Akt/mTOR | 1mg;2mg;5mg;25mg;100mg | |
CAL-101 (PIK3CA inhibitor) | 870281-82-6 | PI3K/Akt/mTOR | 10mg;50mg;100mg;250mg;500mg | |
Duvelisib (IPI-145, INK1197) | 1201438-56-3 | PI3K/Akt/mTOR | 5mg;10mg;25mg;50mg;100mg;1g | |
Eganelisib (IPI-549) (PIK3CA inhibitor) | 1693758-51-8 | PI3K/Akt/mTOR | 5mg;25mg;100mg | |
GSK2126458 (GSK458) (mTOR inhibitor) | 1086062-66-9 | PI3K/Akt/mTOR | 2mg;5mg;10mg;25mg;50mg;100mg | |
GSK2292767 (PIK3CD inhibitor) | 1254036-66-2 | PI3K/Akt/mTOR | 1mg;5mg;10mg;25mg;50mg; | |
Seletalisib (UCB-5857) (PIK3CA inhibitor) | 1362850-20-1 | PI3K/Akt/mTOR | 2mg;5mg;25mg;50mg | |
Tenalisib (RP6530) (PIK3CA inhibitor) | 1639417-53-0 | PI3K/Akt/mTOR | 1mg;5mg;10mg; 25mg;50mg;100mg | |
leniolisib (CDZ 173) (PIK3CA inhibitor) | 1354690-24-6 | PI3K/Akt/mTOR | 1mg;5mg;10mg; 25mg;50mg;100mg | |
Everolimus (mTOR inhibitor) | 159351-69-6 | PI3K/Akt/mTOR | 5mg;25mg;100mg;500mg | |
Miltefosine (AKT1 inhibitor) | 58066-85-6 | PI3K/Akt/mTOR | 100mg;500mg;1g;5g;25g | |
C646 (E1A binding agent protein p300 inhibitor) | 328968-36-1 | Epigenetics | 1mg;5mg;25mg; 100mg;250mg;1g | |
CAY10603 (HDAC1 inhibitor) | 1045792-66-2 | Epigenetics | 1mg;5mg;10mg;25mg;100mg | |
CC-885 (HDAC inhibitor) | 1010100-07-8 | Epigenetics | 5mg;10mg;25mg;50mg;100mg | |
GSK-J1 (KDM5A inhibitor) | 1373422-53-7 | Epigenetics | 10mg;25mg;50mg;100mg | |
GSK-J4 (KDM5B inhibitor) | 1373423-53-0 | Epigenetics | 5mg;10mg;25mg;50mg;100mg | |
I-BET762 (BRD2 inhibitor) | 1260907-17-2 | Epigenetics | 5mg;10mg;25mg; | |
ML324 (KDM4A inhibitor) | 1222800-79-4 | Epigenetics | 5mg;10mg;25mg;50mg;100mg | |
SGC-CBP30 (CBP inhibitor) | 1613695-14-9 | Epigenetics | 5mg;10mg;25mg;50mg;100mg | |
Tubastatin A (HDAC1 inhibitor) | 1252003-15-8 | Epigenetics | 25mg;50mg;100mg;250mg | |
Diroximel Fumarate (HDAC inhibitor) | 1577222-14-0 | Epigenetics | 5mg;10mg;25mg;50mg;100mg | |
1-Methyl-5-p-toluoylpyrrole-2-acetic acid (HDAC inhibitor) | 26171-23-3 | Epigenetics | 250mg;1g;5g;25g | |
Colchicine (BRD4 inhibitor) | 64-86-8 | Epigenetics | 500mg;1g;5g | |
Nabumetone (HDAC inhibitor) | 42924-53-8 | Epigenetics | 250mg;1g;5g;25g | |
Cilomilast (HDAC inhibitor) | 153259-65-5 | Epigenetics | 1mg;5mg;10mg;50mg;100mg | |
Alcaftadine (HDAC inhibitor) | 147084-10-4 | Epigenetics | 25mg;100mg;500mg | |
CUDC-907 (HDAC1 inhibitor) | 1339928-25-4 | Epigenetics | 1mg;5mg;10mg; 25mg;50mg;100mg | |
AZD3965 (MCT1 inhibitor) | 1448671-31-5 | Metabolism | 1mg;5mg;10mg; 25mg;50mg;100mg | |
FIPI (PLD1 inhibitor) | 939055-18-2 | Metabolism | 1mg;5mg;10mg; 25mg;50mg;100mg | |
PFK15 (PFKFB3 inhibitor) | 4382-63-2 | Metabolism | 5mg;25mg;100mg | |
Teriflunomide (DHODH inhibitor) | 108605-62-5 | Metabolism | 25mg;100mg;250mg;1g;5g | |
Vidofludimus (DHODH inhibitor) | 717824-30-1 | Metabolism | 5mg;25mg;50mg;100mg | |
Ziritaxestat (GLPG1690) | 1628260-79-6 | Metabolism | 5mg;10mg;25mg;50mg;100mg | |
7-(2,3-Dihydroxypropyl)theophylline | 479-18-5 | Metabolism | 5g;25g;100g;500g;2.5kg | |
Etodolac (COX-2 inhibitor) | 41340-25-4 | Metabolism | 200mg;1g;5g;25g;100g | |
Etoricoxib (COX-2 inhibitor) | 202409-33-4 | Metabolism | 10mg;50mg;250mg;1g;5g | |
Carprofen (COX-2 inhibitor) | 53716-49-7 | Metabolism | 1g;5g;25g;100g | |
Cerdulatinib (AMP kinase inhibitor) | 1198300-79-6 | Metabolism | 10mg;25mg;50mg; 100mg;200mg | |
Ozagrel (CYP5A1 inhibitor) | 82571-53-7 | Metabolism | 10mg;50mg;250mg;1g;5g | |
Terfenadine (CYP2J2 inhibitor) | 50679-08-8 | Metabolism | 1g;5g | |
Lumiracoxib (COX-2 inhibitor) | 220991-20-8 | Metabolism | 10mg;50mg;100mg; 250mg;1g | |
Darapladib (PLA2-G7 inhibitor) | 356057-34-6 | Metabolism | 5mg;10mg;50mg | |
Ketorolac (COX-1 inhibitor) | 74103-06-3 | Metabolism | 250mg;1g;5g;25g | |
Apremilast (PDE4A inhibitor) | 608141-41-9 | Metabolism | 25mg;250mg;1g;5g;25g | |
Zileuton (5-LOX inhibitor) | 111406-87-2 | Metabolism | 10mg;50mg;250mg;1g;5g | |
Bindarit (FABP4 inhibitor) | 130641-38-2 | Metabolism | 5mg;10mg;50mg | |
DMAT (Casein kinase 2 inhibitor) | 749234-11-5 | Protein tyrosine kinase | 10mg;50mg;250mg | |
Acalabrutinib (ACP-196) (BLK proto-oncogene, Src family tyrosine kinase inhibitor) | 1420477-60-6 | Protein tyrosine kinase | 25mg;50mg;100mg;250mg;1g | |
DCC-2036 (Rebastinib) (ABL1 inhibitor) | 1020172-07-9 | Protein tyrosine kinase | 5mg;10mg;50mg | |
Bafetinib (INNO-406) (ABL1 inhibitor) | 859212-16-1 | Protein tyrosine kinase | 5mg;10mg;25mg;50mg;100mg | |
LY2801653 | 1206799-15-6 | Protein tyrosine kinase | 5mg;10mg;25mg;50mg;100mg | |
PLX5622 (KIT inhibitor) | 1303420-67-8 | Protein tyrosine kinase | 5mg;25mg;50mg; 100mg;250mg | |
Sotrastaurin (PRKCA inhibitor) | 425637-18-9 | Protein tyrosine kinase | 1mg;5mg;25mg;100mg | |
WH-4-023 (LCK inhibitor) | 837422-57-8 | Protein tyrosine kinase | 5mg;10mg;25mg;50mg;100mg | |
Imatinib (STI571) (ABL1 inhibitor) | 152459-95-5 | Protein tyrosine kinase | 1g;5g;25g;100g | |
Ibrutinib (PCI-32765) (BLK inhibitor) | 936563-96-1 | Protein tyrosine kinase | 10mg;50mg;250mg;1g;5g;25g | |
Ponatinib (AP24534) (ABL1 inhibitor) | 943319-70-8 | Protein tyrosine kinase | 10mg;50mg;250mg | |
Dasatinib (ABL1 inhibitor) | 302962-49-8 | Protein tyrosine kinase | 25mg;100mg;500mg; 1g;5g;25g | |
Avapritinib (BLU-285) (KIT inhibitor) | 1703793-34-3 | Protein tyrosine kinase | 1mg;2mg;5mg;10mg; | |
Masitinib (AB1010) (KIT inhibitor) | 790299-79-5 | Protein tyrosine kinase | 25mg;100mg;500mg | |
ONX-0914 (PR-957) (PSMB8 inhibitor) | 960374-59-8 | Proteasome | 5mg;10mg;25mg;50mg;100mg | |
Nemiralisib (GSK2269557) | 1254036-71-9 | Ion channel | 5mg;10mg;25mg;50mg;100mg | |
Thalidomide (TNF-α inhibitor) | 50-35-1 | Immunity and inflammation | 250mg;1g;5g;25g;100g | |
3-(Methylsulfonyl)propanenitrile | 54863-37-5 | Immunity and inflammation | 10mg;50mg;250mg;1g | |
BLZ945 (CSF1R inhibitor) | 953769-46-5 | Immunity and inflammation | 5mg;25mg;100mg | |
CNX-774 (BTK inhibitor) | 1202759-32-7 | Immunity and inflammation | 5mg;10mg;50mg | |
CU-CPT-8m (TLR8 inhibitor) | 125079-83-6 | Immunity and inflammation | 5mg;10mg;25mg;50mg | |
CY 09 (NLRP3 inhibitor) | 1073612-91-5 | Immunity and inflammation | 10mg;50mg;250mg | |
Emavusertib (CA-4948) (IRAK4 inhibitor) | 1801344-14-8 | Immunity and inflammation | 5mg;10mg;25mg;50mg;100mg | |
Epacadostat (INCB024360) | 1204669-58-8 | Immunity and inflammation | 5mg;10mg;25mg;50mg; | |
Evobrutinib (M-2951) (BTK inhibitor) | 1415823-73-2 | Immunity and inflammation | 5mg;10mg;25mg;50mg;100mg | |
IRAK1/4 Inhibitor I (IRAK1 inhibitor) | 509093-47-4 | Immunity and inflammation | 5mg;10mg;25mg;50mg;100mg | |
LFM-A13 (BTK inhibitor) | 244240-24-2 | Immunity and inflammation | 5mg;10mg;25mg;50mg;100mg | |
Lanraplenib (GS-9876) (SYK inhibitor) | 1800046-95-0 | Immunity and inflammation | 5mg;10mg;25mg;50mg;100mg | |
Linrodostat (BMS-986205) | 1923833-60-6 | Immunity and inflammation | 5mg;10mg;25mg;50mg;100mg | |
MCC950 (NLRP3 inhibitor) | 210826-40-7 | Immunity and inflammation | 2mg;5mg;10mg;50mg;100mg | |
ML130 (Nodinitib-1) (NOD1 inhibitor) | 799264-47-4 | Immunity and inflammation | 5mg;25mg;100mg | |
MPO-IN-28 (MPO inhibitor) | 37836-90-1 | Immunity and inflammation | 5mg;25mg;100mg;250mg | |
PF-06282999 (MPO inhibitor) | 1435467-37-0 | Immunity and inflammation | 5mg;25mg;50mg;100mg | |
PF-06840003 (IDO1 inhibitor) | 198474-05-4 | Immunity and inflammation | 5mg;10mg;25mg; | |
PF-06928215 (cGAS inhibitor) | 2378173-15-8 | Immunity and inflammation | 1mg;5mg;10mg;25mg;50mg;100mg | |
PF06650833 (IRAK4 inhibitor) | 1817626-54-2 | Immunity and inflammation | 5mg;25mg;100mg | |
Remibrutinib (LOU064) | 1787294-07-8 | Immunity and inflammation | 5mg;25mg;100mg | |
Setanaxib (GKT137831) (CYBB inhibitor) | 1218942-37-0 | Immunity and inflammation | 5mg;25mg;100mg;250mg;1g | |
Verdiperstat (MPO inhibitor) | 890655-80-8 | Immunity and inflammation | 1mg;5mg;10mg;25mg;100mg | |
Zanubrutinib (BGB-3111) (BTK inhibitor) | 1691249-45-2 | Immunity and inflammation | 2mg;5mg;25mg;50mg | |
Crenolanib (CP-868596) (CSF1R inhibitor) | 670220-88-9 | Immunity and inflammation | 5mg;10mg;25mg;50mg;100mg | |
Orelabrutinib (ICP-022) (BTK inhibitor) | 1655504-04-3 | Immunity and inflammation | 5mg;10mg;25mg;50mg | |
Chloroquine (TLR9 inhibitor) | NSC-187208 | Immunity and inflammation | 250mg;1g;5g;25g | |
Belnacasan (VX-765) (caspase-1 inhibitor) | 273404-37-8 | Immunity and inflammation | 5mg;10mg;25mg; | |
Rapamycin (FKBP1A inhibitor) | 53123-88-9 | Immunity and inflammation | 50mg;250mg;1g | |
Tranilast (RAAS; PGD2 inhibitor) | 53902-12-8 | Endocrinology and hormones | 250mg;1g;5g;25g;100g | |
7-Cl-O-Nec1 (receptor interacting serine/threonine kinase 1 inhibitor) | 852391-15-2 | Apoptosis | 5mg;25mg;50mg; 100mg;250mg | |
GSK'963 (RIPK1 inhibitor) | 2049868-46-2 | Apoptosis | 1mg;5mg;25mg;100mg | |
GSK2982772 (RIPK1 inhibitor) | 1622848-92-3 | Apoptosis | 5mg;10mg;25mg;50mg;100mg | |
GSK2983559 (compound 3) | 1579965-12-0 | Apoptosis | 5mg;10mg;25mg;50mg | |
GSK547 (RIPK1 inhibitor) | 2226735-55-1 | Apoptosis | 5mg;25mg;100mg | |
GSK 583 (RIPK2 inhibitor) | 1346547-00-9 | Apoptosis | 5mg;10mg;25mg;50mg | |
RIPA-56 (RIPK1 inhibitor) | 1956370-21-0 | Apoptosis | 5mg;10mg;25mg; | |
KD025 (SLx-2119) (ROCK1 inhibitor) | 911417-87-3 | Cytoskeleton | 5mg;10mg;25mg; | |
RG7112 | 939981-39-2 | Cell cycle | 5mg;10mg;25mg;50mg;100mg | |
Adavivint (SM04690) | 1467093-03-3 | Cell cycle | 5mg;25mg;100mg | |
BX-795 (AURKB inhibitor) | 702675-74-9 | Cell cycle | 1mg;10mg;50mg;100mg | |
HG-9-91-01 (SIK1 inhibitor) | 1456858-58-4 | Cell cycle | 5mg;25mg;100mg | |
TAK-632 (AURKB inhibitor) | 1228591-30-7 | Cell cycle | 5mg;10mg;25mg;50mg;100mg | |
Takinib (CLK2 inhibitor) | 1111556-37-6 | Cell cycle | 5mg;10mg;25mg;50mg;100mg | |
Tomivosertib (eFT-508) (CLK4 inhibitor) | 1849590-01-7 | Cell cycle | 1mg;5mg;10mg; | |
umbralisib (TGR-1202) (CSNK1E inhibitor) | 1532533-67-7 | Cell cycle | 5mg;10mg;25mg;50mg;100mg | |
Harmine (DYRK1A inhibitor) | 442-51-3 | Cell cycle | 250mg;1g | |
Baricitinib (AAK1 inhibitor) | 1187594-09-7 | Cell cycle | 5mg;10mg;50mg;250mg;1g | |
Dubermatinib(TP-0903) (AURKA inhibitor) | 1341200-45-0 | Cell cycle | 5mg;10mg;25mg;50mg;100mg | |
Apilimod (PIKFYVE inhibitor) | 541550-19-0 | Cell cycle | 25mg;50mg;100mg;250mg;1g |
Binding Agent
Cat.No | Product Name | CAS | Research Category | Size |
Avadomide (CRBN binding agent) | 1015474-32-4 | Ubiquitination | 2mg;5mg;25mg;50mg;100mg | |
Lenalidomide (CRBN binding agent) | 191732-72-6 | Ubiquitination | 50mg;250mg;1g;5g; 10g;25g;100g | |
Iberdomide (CC220) | 1323403-33-3 | Immunity and inflammation | 2mg;5mg;10mg; 25mg;50mg;100mg |
Aladdin:https://www.aladdinsci.com/
